Zepbound for Sleep Apnea Insurance Coverage: The December 2024 Game-Changer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · As of May 2026, confirm directly with your plan

Key Takeaways

• The FDA approved tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity in December 2024
• The SURMOUNT-OSA trials demonstrated AHI reductions of approximately 25 to 30 events per hour at 15 mg
• The OSA indication is reimbursable as sleep medicine, falling outside Medicare Part D weight-loss drug exclusions
• Commercial and Medicare coverage for the OSA indication has expanded substantially through 2025
• Coverage typically requires polysomnography, BMI 30+, and CPAP intolerance or insufficiency documentation

Direct answer

Yes, insurance coverage of Zepbound for moderate-to-severe obstructive sleep apnea has expanded substantially since the FDA's December 2024 approval. The OSA indication is reimbursable as sleep medicine, opening coverage pathways previously closed under weight-loss drug exclusions. Coverage typically requires polysomnography confirming AHI 15 or higher, BMI 30 or higher, and CPAP intolerance, insufficiency, or contraindication documentation. Medicare Part D, commercial plans through major PBMs, and many employer self-funded plans have added coverage under this indication.

Table of contents

1. Why December 2024 matters: the FDA approval
2. What SURMOUNT-OSA demonstrated
3. Why the indication make availableed Medicare coverage
4. Commercial insurance and PBM responses
5. The documentation puzzle: what you need
6. The CPAP question: who qualifies
7. Self-funded employer plans and the OSA workaround
8. Sleep medicine vs primary care prescribing
9. Cost scenarios with OSA coverage
10. The contrary view: should OSA be a coverage pathway for weight loss?
11. Decision framework
12. FAQ
13. Sources

Why December 2024 matters: the FDA approval

On December 20, 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA clinical program, which evaluated tirzepatide in two parallel trials of OSA patients with obesity.

The approval is significant for insurance coverage because it created a non-weight-loss indication for the same molecule that produces substantial weight loss. The medication's primary reimbursable indication, in OSA patients, is sleep medicine. The Medicare Part D weight-loss drug exclusion does not apply. Employer plan exclusions of anti-obesity medications typically do not apply.

For patients with both OSA and obesity, this is the most important coverage development in years. Patients who could not previously obtain coverage under the obesity indication often qualify under the OSA indication with appropriate documentation.

What SURMOUNT-OSA demonstrated

The SURMOUNT-OSA trials, published in the New England Journal of Medicine in June 2024 (Malhotra et al.), enrolled adults with confirmed OSA and obesity:

Trial 1: Patients with OSA not using positive airway pressure (PAP) therapy, randomized to tirzepatide or placebo for 52 weeks.

Trial 2: Patients with OSA on stable PAP therapy, randomized to tirzepatide or placebo for 52 weeks.

Both trials showed significant AHI reduction with tirzepatide. Key results at week 52:

• Mean AHI reduction at 15 mg tirzepatide: approximately 25 to 30 events per hour
• Mean AHI reduction with placebo: approximately 4 to 6 events per hour
• Substantial percentage of tirzepatide patients moved from severe (AHI 30+) to mild (AHI under 15) OSA classification
• Body weight reduction consistent with SURMOUNT-1: approximately 18 to 20% at 15 mg
• OSA-related quality of life measures improved meaningfully

The mechanism appears to be both direct (weight loss reducing upper airway compromise) and possibly indirect (effects on inflammation, autonomic regulation, or other pathways). Studies continue to characterize the mechanism beyond weight loss alone.

Why the indication make availableed Medicare coverage

Medicare Part D was established by the Medicare Modernization Act of 2003 with specific exclusions for several drug categories. Section 1860D-2(e)(2)(A) excludes "agents when used for anorexia, weight loss, or weight gain."

This statutory exclusion has prevented Part D coverage of:

• Wegovy when prescribed for chronic weight management
• Zepbound when prescribed for obesity
• Saxenda when prescribed for weight loss
• Phentermine, Qsymia, Contrave, and other anti-obesity drugs

The exclusion is categorical and statutory; CMS administrative discretion cannot waive it. But the exclusion applies to drugs "when used for" weight loss, not to drugs that produce weight loss as a secondary effect when prescribed for other indications.

The OSA indication for Zepbound falls outside the exclusion. When prescribed for moderate-to-severe OSA, the medication is being used for sleep medicine, not for weight loss. Medicare Advantage and Part D plans have begun covering Zepbound under this indication through 2025 and into 2026.

This is the first major Medicare coverage path for a GLP-1 medication in adults without diabetes (the cardiovascular indication for Wegovy in March 2024 was the second; OSA approval in December 2024 was the third).

Commercial insurance and PBM responses

Major commercial PBMs have updated formulary policies to incorporate the OSA indication:

• CVS Caremark: Added Zepbound for OSA to standard formulary templates with sleep-medicine PA pathway
• OptumRx: OSA indication coverage available with polysomnography documentation
• Express Scripts: OSA pathway with CPAP trial documentation requirement
• Kaiser Permanente: Variable by region; most regions cover under OSA with documentation
• Tricare: OSA indication covered through Express Scripts

Employer self-funded plans that exclude anti-obesity drugs can still cover Zepbound under the OSA indication because sleep medicine is typically a separately covered category.

The documentation puzzle: what you need

Coverage under the OSA indication requires specific documentation:

Polysomnography (sleep study): The diagnostic gold standard. An overnight sleep study at an accredited sleep laboratory measuring apnea-hypopnea index (AHI), oxygen desaturation, sleep stages, and related parameters. Most PA criteria require AHI 15 or higher.

Home sleep apnea testing (HSAT): Some plans accept HSAT for moderate-to-severe OSA documentation. HSAT is more accessible and less expensive than in-lab polysomnography but has limitations for diagnosing mild OSA or complex sleep disorders.

BMI documentation: Current BMI 30 or higher, with weight and height recorded in the medical record.

CPAP trial documentation: If you have used CPAP, documentation of:

• Duration of trial (typically at least 30 days)
• Adherence (CPAP machines record usage data)
• Side effects or intolerance issues
• Inadequate AHI reduction despite use

Sleep medicine physician evaluation: Many plans require sleep medicine physician co-signature on the PA. Primary care physicians can sometimes initiate PA, but sleep medicine support strengthens the documentation.

Contraindication screening: Documentation that you do not have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The CPAP question: who qualifies

The CPAP question is the most consequential one for coverage. The SURMOUNT-OSA trials enrolled patients in two populations: PAP-naive and PAP-treated. Both showed AHI reductions with tirzepatide. But payer PA criteria vary in how they handle the CPAP status question.

Common PA approaches:

• CPAP intolerance: Documented difficulty using CPAP including discomfort, claustrophobia, mask leak issues, or persistent sleep disruption. Generally covered.
• CPAP insufficiency: Documented use of CPAP but inadequate AHI reduction (persistent moderate-to-severe OSA despite use). Generally covered.
• CPAP contraindication: Medical reason CPAP cannot be used. Less common but generally covered.
• CPAP-naive: Patient has not yet tried CPAP. PA approval depends on plan; some require CPAP trial first, others approve initial therapy.
• CPAP-tolerant: Patient uses CPAP successfully with adequate AHI control. Coverage of additional tirzepatide therapy is more difficult.

Patients well-controlled on CPAP face the highest barriers. Coverage may still be possible for residual obesity-related symptoms or comorbidities, but PA criteria are tighter.

Self-funded employer plans and the OSA workaround

Approximately 65% of employer-covered Americans are in self-funded plans. Many self-funded plans exclude anti-obesity medications as a category. For Zepbound, the OSA indication often bypasses this exclusion.

The logic: sleep medicine is typically a covered category in self-funded plans. Treatment of OSA is medically appropriate regardless of the patient's weight status. A medication FDA-approved for OSA, prescribed by a sleep medicine specialist for OSA, with PA submitted under sleep medicine criteria, is generally reimbursable.

This produces an asymmetry. Two patients with the same BMI 35, the same comorbidities, the same need for weight management may have very different coverage outcomes. The patient with confirmed moderate-to-severe OSA can access Zepbound coverage. The patient without confirmed OSA cannot.

For patients with undiagnosed OSA: a sleep evaluation may be clinically appropriate independent of any medication consideration. OSA is significantly underdiagnosed in the United States. Many patients with weight-related metabolic conditions also have undiagnosed OSA. Pursuing a sleep evaluation can identify OSA where it exists.

Sleep medicine vs primary care prescribing

The OSA indication coverage pathway typically requires sleep medicine involvement. Common patterns:

• Sleep medicine physician orders the sleep study, interprets results, and initiates the PA
• Primary care physician initiates with sleep medicine co-signature
• Sleep medicine evaluation followed by primary care management of ongoing therapy

Pure primary care prescribing for the OSA indication, without sleep medicine evaluation, faces higher PA denial rates. Plans want sleep medicine documentation supporting the OSA diagnosis and treatment plan.

Telehealth sleep medicine services have expanded substantially in 2024-2025, providing access to sleep specialist evaluation even in markets without local sleep medicine capacity. Several telehealth platforms specifically offer OSA evaluation and Zepbound coordination.

Cost scenarios with OSA coverage

Scenario	Approximate monthly cost
Medicare Part D OSA covered	$40 to $100 monthly, $2,000 annual cap
Commercial covered, tier 3	$50 to $100
Commercial specialty tier	$100 to $200
With Lilly Savings Card	$25 to $50 (eligibility-limited, commercial only)
Uncovered cash retail	Approximately $1,000
LillyDirect 2.5 mg vial	Approximately $349
LillyDirect 5 mg vial	Approximately $499
Tricare covered	Active duty $0; others ~$14-$76 by pharmacy choice

The contrary view: should OSA be a coverage pathway for weight loss?

The OSA indication has become a workaround for weight-loss coverage exclusions. Patients with both obesity and OSA can access Zepbound coverage that obesity-only patients cannot. This produces some uncomfortable questions worth steelmanning.

The case for treating OSA as a separate indication: OSA is a serious medical condition with its own morbidity and mortality. Cardiovascular disease, motor vehicle accidents, cognitive impairment, and reduced quality of life are all OSA-associated. Treating OSA effectively is medically valuable independent of weight effects. The SURMOUNT-OSA trials demonstrated tirzepatide reduces AHI meaningfully. The medication is appropriately classified as OSA treatment.

The case against the asymmetry: Two patients with identical BMI, identical comorbidities, identical metabolic profiles may have very different coverage outcomes based on whether one has documented OSA. The OSA documentation often requires resources (sleep study access, specialist evaluation) that not all patients can easily obtain. The pathway becomes accessible to patients with better healthcare access, reinforcing existing health disparities.

The deeper question: Why does the system create these workarounds rather than reform the underlying coverage rules for obesity? The Medicare Part D weight-loss exclusion has been a target of advocacy for years. The OSA indication offers a partial workaround but does not solve the underlying inequity.

For individual patients, the OSA pathway is real and accessible when criteria are met. For policy, the asymmetry is worth acknowledging and continuing to address.

Decision framework

If you have diagnosed moderate-to-severe OSA and BMI 30+: Pursue the OSA indication. Work with sleep medicine for documentation. Expect coverage when criteria met.

If you have symptoms suggesting OSA but no diagnosis: Get a sleep evaluation. OSA is significantly underdiagnosed. A sleep study is clinically appropriate independent of any medication consideration.

If you have OSA but tolerate CPAP well: Coverage is more difficult but not impossible. Discuss with sleep medicine whether persistent symptoms or comorbidities support adjunct therapy.

If you have OSA but BMI under 30: The FDA-approved indication requires obesity. Coverage is unlikely for off-label use.

If you have type 2 diabetes and OSA: Consider Mounjaro under the diabetes indication, which is even more accessible than Zepbound under OSA. Same molecule.

FAQ

Will insurance cover Zepbound for sleep apnea? Increasingly yes, since the December 2024 FDA approval.

What does the December 2024 FDA approval cover? Moderate-to-severe OSA in adults with obesity, based on SURMOUNT-OSA.

What did SURMOUNT-OSA show? AHI reductions of approximately 25 to 30 events per hour at 15 mg tirzepatide.

Does Medicare cover Zepbound for sleep apnea? Increasingly yes. The OSA indication falls outside the Part D weight-loss exclusion.

Will commercial insurance cover Zepbound for OSA? Major PBMs have added coverage; specific plan coverage varies.

What documentation do I need for the OSA pathway? Polysomnography, BMI 30+, CPAP trial documentation, sleep medicine evaluation.

Can I get Zepbound if I tolerate CPAP well? Coverage is more difficult; persistent symptoms or comorbidities may support coverage.

What if I have OSA but BMI under 30? FDA approval requires obesity; coverage is unlikely.

Sources

1. FDA, Zepbound (tirzepatide) prescribing information, OSA label expansion, December 2024
2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. June 2024
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022
4. Medicare Modernization Act of 2003, Part D weight-loss drug exclusion provisions
5. Centers for Medicare and Medicaid Services, Part D coverage rules
6. Inflation Reduction Act of 2022, Part D out-of-pocket cap, effective January 2025
7. American Academy of Sleep Medicine, Clinical Practice Guideline for OSA Treatment, 2023 update
8. CVS Caremark, OptumRx, Express Scripts standard formulary policies, 2026
9. Tricare Pharmacy Program Formulary, OSA indication coverage, 2026
10. Eli Lilly, Zepbound clinical and prescribing materials, 2024-2026
11. Kapur VK et al. Clinical Practice Guideline for Diagnostic Testing for Adult OSA. J Clin Sleep Med. 2017
12. National Heart, Lung, and Blood Institute, OSA epidemiology data
13. Senaratna CV et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacy partners. FormBlends does not sell brand-name Zepbound and has no commercial relationship with Eli Lilly, any PBM, or any insurer. Coverage information reflects publicly available data as of May 2026 and continues to evolve.

Compounded Medication Notice. Compounded tirzepatide prepared by 503A pharmacies is a different product from FDA-approved Zepbound. Compounded preparations are not FDA-approved and not interchangeable with brand-name tirzepatide. The SURMOUNT-OSA trial data applies to FDA-approved Zepbound, not to compounded preparations.

Results Disclaimer. AHI reduction, weight loss, and other outcomes from SURMOUNT-OSA and SURMOUNT-1 reflect average effects in study populations. Individual response to tirzepatide for OSA or obesity varies by dose tolerability, adherence, baseline severity, and comorbid conditions.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk A/S. Medicare and Medicare Advantage are administered by the Centers for Medicare and Medicaid Services. References here are informational.